SIETES :: 93166 citas

Resultados de la búsqueda por HEPATITIS C REFINAR BÚSQUEDA

1.

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

2.

Anónimo. Hepatitis C medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to rare occurrence of serious liver injury in some patients with advanced liver disease. FDA MedWatch alert 2019:28 de agosto. [Ref.ID 103166]

3.

Samper E. ¿Y por qué no una farmacéutica pública?. eldiario.es 2018:19 de abril. [Ref.ID 102705]

4.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

5.

Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]

6.

Anónimo. FDA approves HCV drug for patients who fail to respond to prior treatments that inhibit NS5A. DIA Daily 2017:1. [Ref.ID 101910]

7.

Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]

8.

Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]

9.

Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]

10.

Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines for universal health coverage. Lancet 2017;389:1880-1. [Ref.ID 101601]

11.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

12.

Anónimo. Antiviraux à action directe: interaction avec les antivitamine K. Prescrire 2017;37:262. [Ref.ID 101533]

13.

Anónimo. MSF, Medecins du Monde challenge Gilead’s sofosbuvir patent. DIA Daily 2017:1. [Ref.ID 101490]

14.

Campins M, Moraga-Llop FA. Novetats en el calendari vacunal de Catalunya 2016. Butlletí d'Informació Terapèutica 2016;27:60-5. [Ref.ID 101346]

15.

Anónimo. Combination HCV therapy achieves high sustained viral response. DIA Daily 2016:5. [Ref.ID 100926]

16.

Anónimo. Sofosuvir: hypertensions artérielles pulmonaires?. Prescrire 2016;36:746. [Ref.ID 100893]

17.

Anónimo. Patients worldwide turning to “buyers clubs” for access to hepatitis C, HIV medications. DIA Daily 2016:7. [Ref.ID 100881]

18.

Anónimo. Gilead’s hepatitis C drug sales decline. DIA Daily 2016:11. [Ref.ID 100874]

19.

Anónimo. Gilead announces promising trial data for hepatitis C combination drug, setbacks for pulmonary artery hypertension and diabetic kidney disease treatment. DIA Daily 2016:4. [Ref.ID 100839]

20.

Anónimo. European patent office decision means generic sofosbuvir could be available four years sooner. DIA Daily 2016:1. [Ref.ID 100783]